You can access both of our platforms from a single Saxo account.
AI, robotics & blockchain: Key investment considerations
Investment theme
Key takeaways:
- AI, robotics and blockchain are influencing parts of healthcare as providers explore tools for diagnostics, surgery, data management and operational efficiency, but adoption remains uneven.
- Innovation matters because healthcare systems face ageing populations, chronic disease, workforce pressure and rising costs, creating demand for scalable tools that may support care delivery.
- AI is being used in some healthcare settings for image analysis, triage, workflow planning and drug discovery, though outcomes depend on data quality, clinical validation, reimbursement and adoption.
- Robotics can support surgery, rehabilitation, logistics and care tasks, while blockchain is being explored for patient records, pharmaceutical supply chains, claims processing and data integrity.
- Healthcare tech investment considerations include clinical uncertainty, regulation, ethics, integration costs, reimbursement models, public funding and system readiness.
Healthcare is no longer just about doctors, hospitals, and pharmaceuticals. It is becoming a sector increasingly influenced by data and technology, where algorithms assist in diagnostics, robotic arms carry out surgeries, and decentralised systems are being explored for patient data management in some settings. These developments are influencing parts of care delivery and attracting investor attention.
From imaging tools trained on millions of scans to blockchain platforms ensuring patient data integrity, digital tools are being adopted across parts of healthcare, although adoption remains uneven. And as public systems struggle with rising costs, ageing populations, and workforce strain, demand for some tech-enabled solutions is growing, though adoption and revenue models vary by country and provider.
Why innovation matters in healthcare today
Healthcare systems are under increasing pressure. Ageing populations, rising rates of chronic disease, and widespread workforce shortages are straining capacity and resources. At the same time, costs are mounting, both for providers and for governments tasked with maintaining public health infrastructure.
Innovation is no longer a future-facing concern. It is becoming central to how modern health systems operate. Technologies designed to support diagnostics, treatment coordination and administrative workflows are gaining attention. Tools that once belonged in research labs, like AI-enabled triage or predictive analytics, are now being deployed in some hospitals and clinics.
From an investment perspective, this shift may create new growth areas, but outcomes depend on regulation, reimbursement, and implementation. Companies offering tools aimed at addressing inefficiencies in care delivery, resource management, or clinical operations are attracting attention in some markets The focus is shifting from pure scientific breakthroughs to practical, scalable solutions that help healthcare systems operate more efficiently.
AI and healthcare: From diagnostics to drug discovery
Core areas of healthcare already incorporate artificial intelligence:
- Some radiology teams use machine learning tools to support image analysis, although performance depends on clinical context, data quality and approved use.
- Chat-based triage tools may help route patients or collect initial information, depending on how they are designed and used.
- Behind the scenes, AI models are being used in some settings to support workflow planning and estimate bed demand.
These tools are not theoretical; they are in active use.
AI is also being used to support parts of drug discovery and development. Instead of testing thousands of potential drug formulas individually, machine learning may help identify candidates for further testing by analysing vast amounts of data. This approach may help prioritise candidates earlier, but development timelines remain uncertain and clinical validation still drives cost and time.
Interest in companies using AI in diagnostics, early-stage research, patient engagement, and operational efficiency is growing. With cost pressures rising, technologies that may support decision-making, targeting or workflow quality are attracting attention, but commercial success depends on validation, reimbursement and adoption.
Robotics in surgery and care delivery
Robotics in healthcare is now used in some hospitals and healthcare settings for surgeries, rehabilitation, and even logistics. In operating rooms, robots assist with precision tasks in orthopaedics, cardiology, and urology, which may support precision in certain procedures; outcomes such as blood loss or recovery time can vary by procedure, surgeon experience and patient factors.
Beyond surgery, robots support medication delivery, patient lifting, and guided physical therapy. Some hospitals also use automated systems to transport supplies and maintain hygiene, designed to reduce some manual tasks for clinical staff.
Investor interest is growing in companies that offer both robotic hardware and supporting software, although high costs, training needs and system integration can limit adoption. The focus isn’t just on surgical tools but also on robotics integrated with sensors, AI monitoring, and hospital IT systems.
However, scalability remains a challenge. Adoption of robotic technologies is more prevalent in well-funded urban centres, while factors such as cost, training requirements, and system integration pose obstacles in other regions.
Blockchain for data integrity, payments, and transparency
Healthcare systems rely on trust between patients, providers, and insurers. Blockchain is being explored as a way to support data integrity in some use cases by improving traceability and integrity in some designs, although privacy, governance and integration risks remain, and security depends on implementation. Unlike traditional databases, blockchain records are time-stamped, encrypted, and distributed across a decentralised network, making some changes easier to audit, depending on system design and governance.
One potential application is in patient record management. Blockchain-based systems could support permission-based sharing of medical data across hospitals, insurers, and clinics, although implementation varies. Blockchain in healthcare enables accurate, permission-based sharing. In theory, patients can gain greater control over who accesses their medical data and for what duration, although the actual implementation in practice still varies.
Blockchain is also being tested to track pharmaceuticals through supply chains, helping verify drug authenticity and reduce fraud. In insurance and billing, smart contracts could streamline claims by automating approvals and reducing disputes, although adoption is still in its early stages.
While several startups and large healthcare players are piloting blockchain solutions, regulatory frameworks, cost, and system integration remain barriers to widespread use. Still, the possible uses in data integrity, traceability and claims processing continue to attract research, pilots and investor attention.
Biotech and pharmaceutical R&D: Still high risk, but with new tools
Drug development has always carried high uncertainty. Most experimental treatments never make it past clinical trials, and even those that do often face delays or regulatory setbacks.
To address these challenges, biotech firms are increasingly using artificial intelligence (AI) and machine learning to analyse molecular structures, predict protein folding, and identify potential drug targets. In clinical trials, AI aids in designing protocols, selecting suitable patient populations, and supporting trial design, patient selection and scenario analysis, although trial outcomes, timelines and costs remain uncertain.
Pharmaceutical companies are also adopting digital infrastructure to manage large-scale data from genomics, electronic health records, and wearable devices. This can support more targeted research and outcome measurement, depending on data quality, clinical design and regulatory acceptance.
Despite these advances, the industry continues to grapple with long development timelines, regulatory complexities, and intense competition. Still, investors are watching biotech firms that combine strong scientific research with advanced analytics and adaptive trial models, while recognising that clinical, regulatory and funding risks remain significant.
Barriers to healthcare tech adoption: Regulation, ethics, and institutional inertia
Healthcare technology is developing quickly in some areas, but adoption can be slower and uneven. Even after positive trial results, implementation often stalls once they reach hospitals or public systems. Several systemic barriers stand in the way:
Regulatory uncertainty
Healthcare is one of the most tightly regulated sectors in the world, with oversight from bodies like the FDA, EMA, and national health agencies. While this protects patients, it can also lengthen approval, procurement and implementation timelines. Many digital health tools and AI-based solutions don’t fit neatly into existing regulatory categories, creating ambiguity around approval pathways. As a result, companies often face long delays in getting to market, particularly when their products evolve faster than the regulatory frameworks that govern them.
Ethical concerns around AI
As AI becomes more integrated into healthcare decision-making, questions of trust and accountability are becoming more urgent. Bias in training data, lack of transparency in algorithms, and unclear lines of responsibility raise ethical risks. Clinicians may hesitate to rely on AI outputs, while patients may resist care driven by opaque systems.
Resistance to new technology
Hospitals and health systems often rely on legacy software and established workflows that are difficult to update. Integrating new tools can be time-consuming and costly. Procurement cycles are slow, retraining staff takes time, and technical integration isn’t always seamless. In many cases, institutional workflows can be a major obstacle.
Lack of system-level readiness
Even the most promising healthcare technologies can’t scale if the broader ecosystem isn’t equipped to support them. Many markets face budget constraints, fragmented digital infrastructure, and misaligned incentives between payers, providers, and policymakers. These structural limitations—outside any single institution’s control—can make widespread adoption difficult regardless of product quality or clinical need.
Policy and public funding as investment catalysts
Healthtech adoption often depends on more than innovation alone. Public policy and funding play a decisive role in turning promising technologies into scalable solutions.
Governments around the world are backing digital transformation through large-scale programmes.
These efforts may support adoption and clarify pathways in some cases, but they do not remove commercial, regulatory or execution risk. Many also promote public–private partnerships, which may create procurement routes for some companies, although contract timing and adoption vary.
Reimbursement models are evolving, too. More countries now support payments for virtual care, AI-supported diagnostics, and remote monitoring. This helps some pilot projects move toward wider deployment, although reimbursement and procurement decisions vary and revenue is not guaranteed.
Public funding and regulatory alignment can be relevant factors for investors to monitor. Policy shapes where and when adoption takes hold.
AI, robotics, and blockchain are influencing parts of healthcare
Healthcare remains centred on care delivery, clinical evidence and regulated products, but technology is becoming more important in parts of the sector. AI may support diagnostics and drug discovery, robotics may support certain procedures and hospital tasks, and blockchain is being explored for data integrity and claims-related use cases.
This technological transformation is influencing investment flows, with some digital health tools becoming more common in parts of healthcare infrastructure While the sector growth will depend on policy alignment, clinical integration, and system readiness, the direction appears to be toward greater use of digital tools in parts of healthcare, although pace and impact will vary. These technologies are currently influencing how some care pathways are delivered, measured and managed.